Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Germany Passes Japan To Have World’s Lowest Birth Rate, Study

A study says Germany’s birth rate has slumped to the lowest in the world, prompting fears labour market shortages will damage the economy. Germany has dropped below Japan to have not just the lowest birth rate across Europe but also globally, according to the report by Germany-based analysts. Its authors warned of the effects of […]

Read More »

ASCO15: Tiny Clovis Oncology Becomes an Even Bigger Takeover Target as Ovarian Cancer Drug Shrunk Tumors in 82% of Women

June 1, 2015By Riley McDermid, BioSpace.com Breaking News Sr. Editor Boulder, Colo.-based Clovis Oncology (CLVS) has become an even more attractive takeover target after it presented data Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago that showed its ovarian cancer drug shrunk tumors in 82 percent of the […]

Read More »

Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer. At one year, Opdivo demonstrated an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival […]

Read More »

Celldex vaccine helps brain cancer patients live longer: study

Adding an experimental Celldex Therapeutics Inc vaccine that enlists the immune system to fight cancer to standard therapy helped patients with the deadliest type of brain cancer live longer, according to data from a midstage trial presented on Sunday. In the trial of 73 patients whose glioblastoma multiforme (GBM) had recurred after prior therapy, 30 […]

Read More »

Combination of Novartis drugs Tafinlar and Mekinist shows significant survival benefit in patients with metastatic melanoma

EAST HANOVER, N.J., May 31, 2015 /PRNewswire/ — Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar monotherapy alone. This is the first combination of BRAF/MEK inhibitors […]

Read More »

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

RIDGEFIELD, Conn., May 31, 2015 /PRNewswire/ — Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly […]

Read More »

Ibrutinib (IMBRUVICA) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease

SUNNYVALE, Calif., May 31, 2015 /PRNewswire/ — Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA®) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent. The data will be presented today at the […]

Read More »

17% Of Our Genetic Knowledge Is Wrong

Your genes are not your fate. Nonetheless, genes can tell us a lot about our risk for disease, and sometimes they can tell us how to lead healthier lives. The landscape of the human genome is vast and mostly unexplored. There is far, far more that we don’t know than we do know. This is […]

Read More »

Bristol-Myers Squibb Has A Cancer Breakthrough. Here’s Why It Should Cut The Price

A new cancer treatment from Bristol-Myers Squibb saved Gary McLaughlin’s life, but it also landed him in the hospital. McLaughlin, 75, developed melanoma, the deadly skin cancer, just as he was retiring for real. He’d quit his job as a hospital administrator at 70, but spent two years helping his wife run her quilting store before […]

Read More »

China capital to roll out tough anti-smoking laws

Beijing will ban smoking in restaurants, offices and on public transport from Monday, part of unprecedented new curbs welcomed by anti-tobacco advocates, though how they will be enforced remains to be seen. Health activists have pushed for years for stronger restrictions on smoking in China, the world’s largest tobacco consumer, which is considering further anti-smoking […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom